Answers are grounded in this paper and cite their sources.
Induced pluripotent stem (iPS) cells present a seminal discovery in cell biology and promise to support innovative treatments of so far incurable diseases. To translate iPS technology into clinical trials, the safety and stability of these reprogrammed cells needs to be shown. In recent years, different non-viral transposon systems have been developed for the induction of cellular pluripotency, and for the directed differentiation into desired cell types. In this review, we summarize the current state of the art of different transposon systems in iPS-based cell therapies.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: